Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction

Pharmacological Research

Volumn 111, Issue , 2016, Pages 152-154

  Xu, Ming ^a   Tchkonia, Tamar ^a   Kirkland, James L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cellular senescence; Frailty; Insulin resistance; Senolytics

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR; JANUS KINASE; JANUS KINASE INHIBITOR; PROTEINASE; STAT PROTEIN;

AGE RELATED DYSFUNCTION; AGING; CELL AGING; CELLS; CELLULAR SECRETION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; ENZYME INHIBITION; HUMAN; LIFESPAN; MICROENVIRONMENT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SENESCENCE; SENESCENT CELL; SIGNAL TRANSDUCTION; AGE; AGED; ANIMAL; CELL PROLIFERATION; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; FRAIL ELDERLY; FRAILTY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TUMOR MICROENVIRONMENT; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANIMALS; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; CELLULAR SENESCENCE; DRUG DESIGN; FRAIL ELDERLY; FRAILTY; HUMANS; JANUS KINASE INHIBITORS; JANUS KINASES; MOLECULAR TARGETED THERAPY; PHENOTYPE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84975840886     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.05.015     Document Type: Review

References (51)

1. [1] Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., Kirkland, J.L., Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123:3 (2013), 966–972.
2. [2] Hayflick, L., Moorhead, P.S., The serial cultivation of human diploid cell strains. Exp. Cell Res. 25 (1961), 585–621.
3. [3] Munoz-Espin, D., Serrano, M., Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15:7 (2014), 482–496.
4. [4] LeBrasseur, N.K., Tchkonia, T., Kirkland, J.L., Cellular senescence and the biology of aging, disease, and frailty. Nestle Nutr. Inst. Workshop Ser. 83 (2015), 11–18.
5. [5] Palmer, A.K., et al. Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 64:7 (2015), 2289–2298.
6. [6] Dimri, G.P., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:20 (1995), 9363–9367.
7. [7] Paradis, V., et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol. 32:3 (2001), 327–332.
8. [8] Wang, C., et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 8:3 (2009), 311–323.
9. [9] Melk, A., et al. Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. Kidney Int. 63:6 (2003), 2134–2143.
10. [10] Erusalimsky, J.D., Kurz, D.J., Cellular senescence in vivo: its relevance in aging and cardiovascular disease. Exp. Gerontol. 40:8–9 (2005), 634–642.
11. [11] Tchkonia, T., et al. Fat tissue, aging, and cellular senescence. Aging Cell 9:5 (2010), 667–684.
12. [12] Stout, M.B., et al. Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany NY) 6:7 (2014), 575–586.
13. [13] Coppe, J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6:12 (2008), 2853–2868.
14. [14] Kuilman, T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133:6 (2008), 1019–1031.
15. [15] Baker, D.J., et al. Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders. Nature 479:7372 (2011), 232–236.
16. [16] Roos, C.M., et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell, 2016.
17. [17] Zhu, Y., et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14:4 (2015), 644–658.
18. [18] Acosta, J.C., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15:8 (2013), 978–990.
19. [19] Nelson, G., et al. A senescent cell bystander effect: senescence-induced senescence. Aging Cell 11:2 (2012), 345–349.
20. [20] Xu, M., et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife, 4, 2015, e12997.
21. [21] Xu, M., et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl. Acad. Sci. U. S. A. 112:46 (2015), E6301–6310.
22. [22] Meyer, S.C., Levine, R.L., Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin. Cancer Res. 20:8 (2014), 2051–2059.
23. [23] Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9:11 (2009), 798–809.
24. [24] Richard, A.J., Stephens, J.M., Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol. Metab. 22:8 (2011), 325–332.
25. [25] Rane, S.G., Reddy, E.P., JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 9:8 (1994), 2415–2423.
26. [26] Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol. Rev. 228:1 (2009), 273–287.
27. [27] Karaghiosoff, M., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13:4 (2000), 549–560.
28. [28] Shimoda, K., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13:4 (2000), 561–571.
29. [29] Kralovics, R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:17 (2005), 1779–1790.
30. [30] Pardanani, A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27:6 (2013), 1322–1327.
31. [31] Shabbir, M., Stuart, R., Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin. Invest. Drugs 19:3 (2010), 427–436.
32. [32] Hart, S., et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25:11 (2011), 1751–1759.
33. [33] Fridman, J.S., et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184:9 (2010), 5298–5307.
34. [34] Ghoreschi, K., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186:7 (2011), 4234–4243.
35. [35] Toso, A., et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9:1 (2014), 75–89.
36. [36] Harel, S., et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci. Adv., 1(9), 2015, e1500973.
37. [37] Price, F.D., et al. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. Nat. Med. 20:10 (2014), 1174–1181.
38. [38] Quintas-Cardama, A., Preclinical characterization of the selective JAK1/2 inhibitor INCB04: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:15 (2010), 3109–3117.
39. [39] Baker, D.J., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530:7589 (2016), 184–189.
40. [40] Moiseeva, O., et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell 12:3 (2013), 489–498.
41. [41] Laberge, R.M., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17:8 (2015), 1049–1061.
42. [42] Laberge, R.M., et al. Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell 11:4 (2012), 569–578.
43. [43] Harrison, D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:7253 (2009), 392–395.
44. [44] Neff, F., et al. Rapamycin extends murine lifespan but has limited effects on aging. J. Clin. Invest. 123:8 (2013), 3272–3291.
45. [45] Martin-Montalvo, A., et al. Metformin improves healthspan and lifespan in mice. Nat. Commun., 4, 2013, 2192.
46. [46] Verstovsek, S., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366:9 (2012), 799–807.
47. [47] Michaud, M., et al. Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 14:12 (2013), 877–882.
48. [48] Verstovsek, S., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363:12 (2010), 1117–1127.
49. [49] Kirkland, J.L., Tchkonia, T., Clinical strategies and animal models for developing senolytic agents. Exp. Gerontol. 68 (2015), 19–25.
50. [50] Demaria, M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31:6 (2014), 722–733.
51. [51] Helman, A., et al. p16-induced senescence of pancreatic beta cells enhances insulin secretion. Nat. Med., 2016.